Recent Updates
Recently added Catalysts
VOGX Positive Sentiment

Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes

Key Takeaway: Vogenx, Inc. (VOGX) will join the Russell 2000, Russell 3000, and Russell Microcap indexes in December 2026. This inclusion follows the company's August 2026 IPO and takes effect after market close on December 11. The move broadens visibility for institutional investors as Vogenx advances mizagliflozin in its Phase 2b EMERGE study for post-bariatric hypoglycemia.
Price reaction · baseline $12.34 (2026-11-18 close) · hit pre-market · clean, no other VOGX news in the window
day 0 close · peak
+3.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Vogenx joins major Russell indexes shortly after IPO.
  • Inclusion enhances visibility with institutional investors.
  • Company advances mizagliflozin in Phase 2b study.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~95 mo
Minimal dilution risk
Lead asset
Mizagliflozin
Phase 2 · Postbariatric Hypoglycemia

Full Press Release Details

The first and only All-in-one subscription platform offering all of your PR Distribution and Media Outreach Tools in one single solution. Monthly & Annual Subscriptions.
Find & create journalist lists with the most up to date database in the industry.
Personalize and customize your pitch for maximum engagement.
Discover your brand, industry, and competitor mentions.
Now you can track every mention, every conversation, and every shift in sentiment — all from the platform you're already using.
Turn your PR data into actionable intelligence with comprehensive reporting and analytics on every campaign.
Catch issues before our editors do. ACCESS Verified gives you a real-time first pass on your press release so you can submit with confidence — every time.
The first and only All-in-one subscription platform that offers you the ability to manage all of your IR communications needs from a single source. Explore our IR subscriptions
Explore how you can upgrade your IR Site today.
Ensure your IR Site is accessible for your entire audience.
Experience seamless calls with our dedicated team of domestic operators.
Easily send your releases out with quick turnarounds and no extra fees.
Host your day knowing you've got the most experienced webcast team in the industry.
Provide a secure and confidential reporting channel to protect your organization and employees.
Streamline your PR & IR needs with one platform.
Easily schedule and manage your investor meetings with our comprehensive and easy to use software.
Our PR and IR tools are designed to meet all necessary regulatory requirements, giving you the confidence to communicate effectively and compliantly. Streamline your communications needs today with our one-stop shop offering.
Whether a startup or established brand, we deliver the support, targeted distribution, media outreach, and flexible pricing & payment options needed to amplify your story with confidence.
We simplify the process of delivering success for both you and your clients. We understand the importance of getting it right, equipping you with seamless billing, flexible plans and payment structures, and clear reporting and analytics to ensure every campaign runs smoothly and achieves measurable results.
We understand the need to manage high volume of press release distribution efficiently. That's why we offer a dedicated API designed specifically for our legal customers, delivering a streamlined, simple process that ensures value and ease at every step.
We understand the importance of cost efficiency for high-volume partners, which is why we offer bulk discounts tailored to meet your needs while maximizing value.
Designed for brands that need help consistently fueling their content strategy and calendar with optimized press releases, blogs, and more…
Tailored for brands with a solid content strategy seeking support for effectively reaching and engaging the media.
Made for brands that need more comprehensive support building and managing their content strategy, media outreach and engagement plan.
Personalized support to optimize your platform, including tailored journalist list creation, pitch guidance, and monitoring setup.
Continual support and management including ongoing list creation, pitch creation and modifications, monitoring adjustments, and additional reporting and analytics review.
Press Release creation and optimization for SEO and audience engagement
Back to the Newsroom Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes Thursday, 19 November 2026 08:30 AM
Inclusion in the Russell 2000®, Russell 3000®, and Russell Microcap® follows the Company's August 2026 initial public offering and takes effect with FTSE Russell's December 2026 reconstitution
RALEIGH, NC / ACCESS Newswire / November 19, 2026 / Vogenx, Inc. (Nasdaq:VOGX), a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it is set to join the broad-market Russell 2000®, Russell 3000® Index, and Russell Microcap® Index as part of FTSE Russell's December 2026 semi-annual reconstitution of the Russell US Indexes. Membership will take effect after the U.S. equity markets close on Friday, December 11, 2026, according to the preliminary list of additions FTSE Russell published on November 13, 2026.
Russell index membership is determined by objective, rules-based criteria, chiefly total market capitalization as of the rank day. The December 2026 reconstitution is the first December reconstitution of the Russell US Indexes in more than three decades, following FTSE Russell's move to a semi-annual (June and December) schedule this year.
"Joining the Russell indexes just four months after our IPO is an important milestone for Vogenx," said James Green, Chief Executive Officer of Vogenx. "Index inclusion broadens our visibility with institutional and index-based investors at a time when we are advancing mizagliflozin in our Phase 2b EMERGE study for post-bariatric hypoglycemia, a serious condition with no FDA-approved treatment. We look forward to engaging with a wider investor base as we work toward key clinical milestones."
The Russell US Indexes, maintained by FTSE Russell, are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. The Russell 3000® Index measures the performance of the broad U.S. equity market, and the Russell 2000® Index, a subset of the Russell 3000, is a leading benchmark for U.S. small-capitalization companies. Beginning in 2026, the Russell US Indexes are reconstituted twice a year, in June and December.
Mizagliflozin is an investigational, first-in-class, orally administered, minimally absorbed small-molecule inhibitor of the sodium-dependent glucose transporter 1 (SGLT1). Designed to act locally in the small intestine, mizagliflozin reduces and delays intestinal glucose absorption, lowering postprandial glucose absorption. It has been studied in more than 500 subjects across 10 clinical studies. Vogenx holds an exclusive license to mizagliflozin from Kissei Pharmaceutical Co., Ltd. covering all territories outside Japan, Korea and Taiwan.
Vogenx, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, North Carolina, focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism where there is significant unmet medical need. The Company is developing its lead product candidate, mizagliflozin, for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome. For more information, please visit https://vogenx.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected inclusion in the Russell 3000®, Russell 2000® and Russell Microcap® Indexes, the timing thereof, the anticipated benefits of index inclusion, and the Company's clinical development plans and milestones. Index membership remains subject to FTSE Russell's final determination. Words such as "anticipate," "believe," "expect," "intend," "may," "plan," "will" and similar expressions are intended to identify forward-looking statements. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described under "Risk Factors" in the Company's filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this release, and Vogenx specifically disclaims any obligation to update them, except as required by law.

Frequently Asked Questions

When will Vogenx join the Russell Indexes?

Vogenx will join the Russell Indexes after the markets close on December 11, 2026.

What is mizagliflozin used for?

Mizagliflozin is being developed for post-bariatric hypoglycemia and other conditions.

What does Russell Index membership mean for Vogenx?

Membership increases visibility with institutional and index-based investors.

How long after the IPO did Vogenx join the indexes?

Vogenx is joining the indexes just four months after its IPO.

Last updated: Nov 19, 2026